Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Colorectal cancer (CRC) is a significant global health concern.
• Activating mutations in BRAF are found in approximately 10% of metastatic CRC cases.
• BRAF mutations are associated with a poorer prognosis in CRC.

Purpose of the Study:

• To review the clinical and pathological features of BRAF-mutant colorectal cancer.
• To discuss the translation of preclinical findings into clinical therapeutic strategies.
• To highlight novel treatment options for patients with BRAF-mutant metastatic CRC.

Main Methods:

• Literature review of preclinical studies and clinical trials.
• Analysis of therapeutic strategies targeting the MAPK pathway.
• Evaluation of combination therapies including BRAF, MEK, and EGFR inhibitors.

Main Results:

• BRAF inhibitors alone show limited efficacy in BRAF-mutant CRC compared to other cancers.
• Combination therapies targeting BRAF, MEK, and EGFR present a promising strategy.
• Recent advancements focus on overcoming resistance mechanisms to targeted therapies.

Conclusions:

• Simultaneous targeting of multiple MAPK pathway drivers improves outcomes in BRAF-mutant CRC.
• Targeted therapies and immunotherapy offer significant potential for this patient population.
• Further research is needed to optimize treatment sequencing and combination strategies.